Search Results

You are looking at 1 - 10 of 115 items for :

  • "symptom burden" x
  • Refine by Access: All x
Clear All
Full access

Jie Liu, Qingxi Yu, Xin Shelley Wang, Qiuling Shi, Jun Wang, Fan Wang, Simeng Ren, Jiayue Jin, Baojin Han, Wenzheng Zhang, Xueyao Su, Shuanghu Yuan, and Hongsheng Lin

The goal of this multicenter randomized study was to determine the efficacy and toxicity of CKI in reducing the severity of radiation damage and its corresponding benefit on symptom burden in patients with lung cancer, as well as to assess clinical and

Full access

Daniel E. Lage, Areej El-Jawahri, Charn-Xin Fuh, Richard A. Newcomb, Vicki A. Jackson, David P. Ryan, Joseph A. Greer, Jennifer S. Temel, and Ryan D. Nipp

symptom burden and other clinical outcomes. Notably, hospitalized patients with cancer may actually experience more severe symptom burden and functional decline than those in the outpatient setting. 3 These patients are also at risk for poor clinical

Full access

Alexandra K. Zaleta, Melissa F. Miller, Julie S. Olson, Eva Y.N. Yuen, Thomas W. LeBlanc, Craig E. Cole, Shauna McManus, and Joanne S. Buzaglo

quality of life (QoL), including fatigue, pain, breathlessness, muscle weakness, and peripheral neuropathy, 11 , 12 which can negatively impact work, social, and familial roles. 13 Research has shown patients with MM experience greater symptom burden and

Full access

Emily van Seventer, J. Peter Marquardt, Amelie S. Troschel, Till D. Best, Nora Horick, Chinenye Azoba, Richard Newcomb, Eric J. Roeland, Michael Rosenthal, Christopher P. Bridge, Joseph A. Greer, Areej El-Jawahri, Jennifer Temel, Florian J. Fintelmann, and Ryan D. Nipp

function and increased mortality. 2 , 13 However, data are lacking to understand how patients’ muscle mass and radiodensity are associated with their symptom burden and healthcare utilization. Hospitalized patients with advanced cancer represent a group

Full access

Meagan S. Whisenant, Faith A. Strunk, Debasish Tripathy, and Loretta A. Williams

described their experience in single qualitative interviews. Content analysis was used to define the symptom burden content domain. An expert panel scored the relevance on a 0–4 scale (4 = relevant) of the symptoms identified from the qualitative interviews

Full access

Ruben Mesa, Jeanne Palmer, Prithviraj Bose, Stephen Oh, Raajit Rampal, Sarah Buckley, Karisse Roman-Torres, Srdan Verstovsek, and John Mascarenhas

INTRODUCTION : Moderate to severe thrombocytopenia is a recognized marker of poor prognosis and high symptom burden in patients with myelofibrosis (MF). Data from the MPN-QOL study group (Scotch AH, Leuk Res 2017) showed that patients with

Full access

Linda Watson, Siwei Qi, Claire Link, Andrea DeIure, Arfan Afzal, and Lisa Barbera

randomized controlled trial that showed that patients who routinely reported PROs electronically, with real-time symptom triage and follow-up telephone assessments for patients with high symptom burden, were less frequently admitted to the ED (34% vs 41%) or

Full access

Ruth Elisa Eyl-Armbruster, Melissa S.Y. Thong, Prudence R. Carr, Lina Jansen, Jenny Chang-Claude, Michael Hoffmeister, Hermann Brenner, and Volker Arndt

with survivors with a high baseline HLS, survivors with low baseline HLS had significantly lower functioning (physical, role, and emotional) and poorer global health/QoL ( Figure 1 ). Concerning symptom burden, survivors with low baseline HLS were more

Full access

Ryan D. Nipp, Leah L. Thompson, Brandon Temel, Charn-Xin Fuh, Christine Server, Paul S. Kay, Sophia Landay, Daniel E. Lage, Lara Traeger, Erin Scott, Vicki A. Jackson, Nora K. Horick, Joseph A. Greer, Areej El-Jawahri, and Jennifer S. Temel

adults with cancer who may experience poor outcomes. Although older patients with cancer represent an increasing and heterogeneous population with diverse needs, little research has sought to identify those at risk of experiencing high symptom burden or

Full access

Daniel C. McFarland, Heather Polizzi, John Mascarenhas, Marina Kremyanskaya, Jimmie Holland, and Ronald Hoffman

Background The prevalence of distress, anxiety, and depressive symptoms has not been assessed by standard measures in patients with BCR-ABL–negative myeloproliferative neoplasms (MPNs). This is perhaps surprising given the large symptom burden